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Abstract
Background: Acquired hepatocerebral degeneration (AHD) refers to a chronic neurological syndrome in patients with advanced hepatobiliary diseases. This
comprehensive review focuses on the pathomechanism and neuroimaging findings in AHD.
Methods: A PubMed search was performed using the terms ‘‘acquired hepatocerebral degeneration,’’ ‘‘chronic hepatocerebral degeneration,’’ ‘‘Non-Wilsonian
hepatocerebral degeneration,’’ ‘‘cirrhosis-related parkinsonism,’’ and ‘‘manganese and liver disease.’’
Results: Multiple mechanisms involving the accumulation of toxic substances such as ammonia or manganese and neuroinflammation may lead to widespread
neurodegeneration in AHD. Clinical characteristics include movement disorders, mainly parkinsonism and ataxia-plus syndrome, as well as cognitive impairment
with psychiatric features. Neuroimaging studies of AHD with parkinsonism show hyperintensity in the bilateral globus pallidus on T1-weighted magnetic resonance
images, whereas molecular imaging of the presynaptic dopaminergic system shows variable findings. Ataxia-plus syndrome in AHD may demonstrate high-signal
lesions in the middle cerebellar peduncles on T2-weighted images.
Discussion: Future studies are needed to elucidate the exact pathomechanism and neuroimaging findings of this heterogeneous syndrome.
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Introduction
Acquired hepatocerebral degeneration (AHD) refers to a neurolo-
gical syndrome consisting of various movement disorders and cognitive
impairment in advanced liver cirrhosis (LC) or portosystemic shunt.
Since the first detailed report by Victor et al. in 1965,1 AHD is now
more widely recognized by physicians. Over the past several decades,
many nomenclatures have been used for this heterogeneous syndrome,
adding to the difficulty in understanding AHD. Furthermore, in the era
when computed tomography was the only imaging modality available,
the diagnosis of AHD could only be made with reference to the patient’s
neurologic manifestations, laboratory findings, and the presence of LC.
The diagnosis was challenging because it was sometimes difficult to
differentiate from Wilson disease (WD). It was not until about 20 years
ago that the discovery of symmetric hyperintensities in the bilateral
globus pallidus and putamina on T1-weighted magnetic resonance
imaging (MRI) sparked research into AHD. Neurological symptoms and
signs may be attributed to the accumulation of toxic substances resulting
from dysfunctional clearance as found in diverse chronic hepatobiliary
diseases. More specifically, manganese accumulation has been recog-
nized as a key feature in the pathomechanism of AHD, mainly present-
ing with parkinsonism. The development of neuroimaging modalities
to evaluate the integrity of presynaptic dopamine neurons provided
new clues to the mechanism in which accumulating manganese acts on
dopaminergic motor pathways, leading to parkinsonism. In contrast,
AHD with ataxia-plus syndrome may have different pathomechanisms.
These patients exhibit hyperintensities in the cerebellum and middle
cerebellar peduncles (MCPs) on T2-weighted MRI. There are many
unresolved issues related to this disease including its clinical character-
istics, neuroimaging findings, and treatment strategies.
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This review article addresses the basic concepts and recent updates
on AHD, mainly focusing on the pathomechanism and neuroimaging
findings associated with each distinct clinical syndrome.
Methods
We conducted a search for articles using the PubMed database from
November 2016 to June 2017. The specific search terms included
‘‘acquired hepatocerebral degeneration’’ (81 articles), ‘‘chronic hepa-
tocerebral degeneration’’ (49 articles), ‘‘Non-Wilsonian hepatocerebral
degeneration’’ (25 articles), ‘‘manganese and liver disease’’ (69 articles),
‘‘portosystemic encephalopathy’’ (21 articles), ‘‘cirrhosis-related par-
kinsonism (8 articles),’’ and ‘‘hepatic myelopathy’’ (43 articles). We
reviewed the published articles by search terms and selected 188
articles published in English using the following criteria: 1) chronic
neurologic manifestations, 2) the presence of hepatobiliary diseases or
portosystemic shunt, and 3) co-existing acute hepatic encephalopathy.
Duplicated articles, articles about WD, and articles about pediatric
patients with AHD were excluded. The articles were published between
1965 and 2017. Randomized controlled studies are rare; most publica-
tions on AHD are reviews, case series, and retrospective clinical studies.
Regarding the frequencies of clinical symptoms, we cited the data
presented in the literature when available. For symptoms for which the
frequency was not provided in previous reports, we analyzed the
frequencies of symptoms by reviewing 76 reports (including 374 patients)
that provided detailed descriptions of the clinical features.
AHD
Epidemiology
The exact prevalence and incidence of AHD are unknown because
its epidemiology has rarely been reported. The prevalence of AHD in
chronic liver disease is estimated to be 1–2%.2–4 AHD prevalence has
been reported as higher in males than in females,1,2,4–7 but others
reported conflicting results.3,8 This discrepancy in the reported
prevalence rates between sexes may be attributable to the prevalence
of LC, which is more common in males (72.7%) than in females
(27.3%).9 Furthermore, male sex may itself be a risk factor for AHD.2
A variety of movement disorders, mainly parkinsonism and cerebel-
lar ataxia, have been found to occur in about 60% of patients with
AHD.3,7 Parkinsonism is present in 10.5–25% of AHD patients.3,5,7 In
addition, parkinsonism is present in 3.5–4.2% of patients with LC.10,11
The frequencies of symptoms in AHD or LC are variable, which may
explain the variation in the characteristics of the reported patient
groups and methodologies used in different studies.
Etiology and pathology
AHD occurs in a huge variety of advanced hepatobiliary diseases.
Portosystemic shunting is an important predisposing factor for AHD
development because its presence may allow toxic substances to enter
the brain via the systemic circulation, ultimately resulting in toxic
substance accumulation in the brain.12 No relationship has been found
between the type of hepatobiliary disease and AHD.13 Patients with
AHD have moderate to severe LC (Child-Pugh class B and C);2,3,5
however, disease severity may not be associated with AHD develop-
ment given that liver function may be normal in the presence of
portosystemic shunting.13
The duration between the diagnoses of liver disease and a neuro-
logic syndrome varies widely from 1 to 33 years,3,8 suggesting that dura-
tion may not be associated with AHD development. Acute hepatic
encephalopathy (HE) can occur before and after AHD onset. History
of acute HE, which has been reported to be present in 24 out of
27 patients,1 has been suggested as a risk factor for AHD development.
AHD seems to follow prolonged time in a coma or multiple episodes of
severe HE,14 but a relationship between HE severity or frequency and
AHD has not been established.13
The extent of pathologic involvement in AHD is wide and diffuse
and includes any areas from the cerebral cortices to the brainstem and
cerebellum. Although only 32 autopsy cases have been reported, the
pathologic findings were similar. Pathologic features do not necessarily
correlate with clinical findings.1 Neuronal cell loss and spongy dege-
neration frequently affect deep cortical areas, especially layers III–V of
the frontal, parietal, and occipital areas, while sparing the temporal
cortex.15 In the cortices, laminar and pseudolaminar necroses are
typical pathologic features. Neuronal loss and atrophy are observed
throughout the deep nuclei including the lenticular, caudate, thalamic,
and subthalamic nuclei and cerebellum.16 Microscopically, polymicro-
cavitation is found in cortical areas and the basal ganglia. Alzheimer
type II astrocytosis invariably occurs in areas affected by polymi-
crocavitation, as well as those that appear macroscopically normal
(Figure 1).12,13,15 Postmortem examination of patients with HE revea-
led central pontine myelinolysis and extrapontine myelinolysis com-
bined with classic pathological findings of AHD.17,18 Furthermore,
subacute combined degeneration may be related to white matter
lesions in patients with AHD.19
Figure 1. Pathology of AHD. Alzheimer type II astrocyte showing large pale
nuclei with basophilic nuclei. Reproduced with permission from Ferrara et al.12
AHD, Acquired Hepatocerebral Degeneration.
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Pathomechanism
The exact pathophysiology of AHD has yet to be fully elucidated.
Among multiple hypotheses that have been proposed, none embraces
all the plausible mechanisms that are thought to be involved in its
development (Figure 2). Accumulation of toxic substances like manga-
nese or ammonia secondary to defective liver clearance mechanisms
may facilitate AHD development. Although hyperammonemia was the
focus of attention in early research on AHD, the manganese theory has
gained more support over the past two decades. Hyperammonemia
may play a role in AHD development due to its influence on astrocyte
function. Astrocytes have a homeostatic function in glutamate uptake/
release through glutamine synthetase.20 Increased concentrations of
ammonia in chronic liver disease inhibit glutamate removal by gluta-
mine synthetase in astrocytes, which leads to glutamine accumulation
and low-grade brain edema.21 A higher ammonia concentration can
activate nitric oxide synthase signal transduction, which implicates
nitrosative stress in the central nervous system (CNS). Effects of an
increased ammonia level may synergize with other actions stimulated
by pro-inflammatory cytokines and toxic metals like manganese.22
Accumulation of manganese may play a major role in AHD patho-
physiology. The manganese theory was supported by MRI findings
including high signal intensities in the bilateral globus pallidus and
adjacent areas on T1-weighted images (T1WI). Such features are
identical to those found in patients with high exposure to manganese
in association with occupational manganism and total parenteral
nutrition.23 There are also similar clinical features between manganism
and AHD, such as increased manganese levels in whole blood and
cerebrospinal fluid. High concentrations of manganese in brain tissue
support the theory that neurotoxicity by manganese has a key role in
the pathomechanism of AHD.24 In contrast, increased manganese
levels in blood do not predict neurological impairment in AHD,
indicating a lack of a cause-effect relationship. Despite this find-
ing, manganese may be responsible for parkinsonism in AHD by
significantly altering the dopaminergic neurotransmission.25 In the
human diet, manganese intake comes from sources such as nuts, rice,
whole grains, and multivitamins. Only 3–5 % of ingested manganese is
absorbed through the gastrointestinal tract, which is mainly excreted
through the biliary system. In advanced hepatobiliary disease, dysfun-
ctional manganese removal leads to its accumulation in the brain.
Iron deficiency anemia, a common nutritional problem in the general
population and patients with liver disease, may worsen manganese
accumulation because manganese and iron share common uptake
transporters.26 Recently, progress has been made in understanding the
mechanisms of manganese uptake into the CNS. Neurotoxicity occurs
with high intracellular concentrations of manganese, so it is essential
to understand the actions of manganese transporters in manganese-
induced neurotoxicity. Membrane importers of manganese into the
cell include the divalent metal transporter 1 (DMT1), zinc transporters
ZIP8 and ZIP14, citrate transporter, choline transporter, dopamine
transporter (DAT), transferrin receptor (TfR), and calcium channels.
Both the DMT1 and TfR are the primary transporters of manganese
into the cell. Furthermore, manganese has high affinity for DMT1,
which is highly expressed in the basal ganglia including the globus
pallidus and striatum.27 As a result, the basal ganglia is more suscep-
tible to intracellular accumulation of manganese and subsequent neuro-
toxicity. Proteins involved in manganese efflux include SLC30A10,
ATP13A2 (also known as PARK9), ferroportin, and SPCA1.28 Of these,
SLC30A10 and ATP13A2/PARK9 have been associated with the
involvement of manganese in AHD. SLC30A10 is mainly expressed in
the basal ganglia and liver, and mutations in the SLC30A10 gene are
associated with familial parkinsonism, dystonia, hypermanganesemia
polycythemia, and LC.29 ATP13A2 mutations cause Kufor-Rakeb syn-
drome, characterized by early onset parkinsonism, spasticity, supranuclear
Figure 2. The Putative Pathomechanism in AHD. The exact pathomechanism in AHD remains unclear, but the putative pathomechanism includes complex
actions between toxic substance accumulation, neuroinflammation, oxidative stress, and inducible nitric oxide (nitrosative stress). AHD, Acquired Hepatocerebral
Degeneration.
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gaze palsy, and dementia.30 Based on these findings, membrane
transporters of manganese may play key roles in the regional specifi-
city and neurologic manifestations of manganese accumulation in
the brain.
Neuroinflammation may contribute to AHD development.22,31 In
the acute phase of neuronal injuries cause by metabolic insults, low-to-
intermediate inflammation has positive effects on neuronal injuries
because it facilitates debris removal. Conversely, low-to-high intensity
of inflammation in the chronic phase such as in chronic liver disease
leads to greater release of pro-inflammatory cytokines and reactive
oxygen species. This maladaptive inflammatory response hinders
recovery of neuronal damage and synaptic plasticity. Chronic neuroin-
flammation may contribute to widespread neurodegeneration, which
reinforces a chronic inflammatory state. Multiple mechanisms includ-
ing toxic substance accumulation, neuroinflammation, and oxidative
and nitrosative stress may act synergistically to cause neurodegenera-
tion in AHD.
Clinical characteristics
The age of onset, which may be related to the duration of under-
lying hepatobiliary disease, is variable. Symptom onset is generally
insidious despite previous reports describing exceptional cases with
acute symptom development.32,33 In contrast to the reversible course
of acute HE, AHD is generally characterized by a chronic, progressive,
and irreversible course without spontaneous recovery,1,5,13 with the
exception of cases that recover after liver transplantation (LT) (see
‘‘Treatment’’).34,35
Neurologic symptoms and signs include the three following features:
1) movement disorders, mainly parkinsonism and ataxia-plus
syndrome, 2) cognitive impairment and psychiatric symptoms, and
3) myelopathy.
Parkinsonism and other movement disorders. Movement disorders are
the most common neurologic manifestations of AHD. About 20%
of AHD patients have parkinsonism.5 AHD-related parkinsonism is
mostly characterized by symmetric parkinsonism, early gait disturbance
or falls, prominent postural or action tremor, mild cognitive impair-
ment, and variable response to levodopa therapy (Video 1 & 2).5,8
The clinical course can vary; some patients may rapidly worsen, while
others may be stable. Both isolated parkinsonism and parkinsonism
with other accompanying movement disorders can be seen in AHD.
These features of parkinsonism may distinguish AHD from typical
Parkinson’s disease (PD), which is characterized by the asymmetric,
pill-rolling type of rest tremor, late postural instability or gait
disturbance, and excellent response to levodopa. Only rare reports
on AHD have described parkinsonism resembling typical PD.13,36 Rest
tremor is rarely observed in parkinsonism related to AHD and is
mostly accompanied by postural or action tremor in one or both
hands.5,13,37 Rest tremor without prominent postural tremor is much
rarer than rest tremor with postural or action tremor. Postural and
intentional tremors are commonly seen and characterized by a large
amplitude and frequency of 4–7 Hz.13 Dysarthria related to parkinsonism
in AHD is characterized by slow, monotonous, and slurred speech.
Chorea,1,12,13 orolingual dyskinesia,15 dystonia,5,6 and pyramidal tract
signs1 can be seen in AHD patients, whereas ballism has rarely been
reported.38 Our analysis of 76 studies including 374 patients showed
that 36 (9.6%) had chorea and 28 (7.5%) had dystonia. Cranial
dyskinesia may occur alone or together with chorea in the limbs, being
observed in 7.5% (28) of all 374 patients and in 77.8% (28) of the
36 patients with chorea. Cranial dyskinesia, characterized by protru-
sion and retraction of the tongue and lips accompanied by grimacing
movements of the face, may be the characteristic motor pheno-
type in AHD.12,15 Generalized choreoathetotic movements in AHD
may resemble those seen in Huntington’s chorea. The severity,
extent, and accompanying features of hyperkinetic movements vary.1
Video 1. Case 1: A 63-Year-Old Male with a 3-Year History of
Tremor. He presented with masked face, hypophonia, micrographia, mild
action tremor of hands, and mild rigidity and bradykinesia. With levodopa
300 mg/day, there was marked improvement of tremor, micrographia,
and bradykinesia.
Video 2. Case 2: A 38-Year-Old Male with Severe Tremors of the
Tongue, Jaw, and Both Hands. He presented with severe resting and
postural tremors in the arms, masked face, mild bradykinesia, and rigidity,
which were not responsive to levodopa.
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Hyperkinetic movement disorders usually occur together but can occur
separately. Abnormal movements are frequently accompanied by
ataxia, but in our analysis, it was absent in 27.8% of patients with
chorea and 32.1% of those with dystonia. No report to date has
described ballism accompanied by ataxia, but this may be due to
selection bias as these movement disorders are rarely observed in
patients with AHD. Myoclonus/asterixis is less common in AHD than
in acute HE and can be seen in AHD associated with HE.3,38
Ataxia-plus syndrome. Ataxia-plus syndrome, referring to predomi-
nant ataxia combined with other signs, is commonly observed in AHD
and is characterized by ataxic dysarthria, absence of nystagmus, and
limb and gait ataxia.1,3,39 The frequency of ataxia-plus syndrome has
not been reported. Our analysis of 374 patients in 76 studies revealed
that 114 (30.5%) had ataxia-plus syndrome, whereas Victor et al.
reported that all patients except one had cerebellar ataxia.1 Nystagmus
may occasionally be present but rarely so.1 Dysarthria associated with
ataxia-plus syndrome is common in AHD and possesses characteristic
features of scanning, slurred, staccato, and explosive speech.39 Postural
tremor, dystonia, or chorea co-occur with ataxia. Pure cerebellar syn-
drome with cerebellar atrophy has been reported in rare instances.40
Ataxia may be attributable to lesions in the cerebellum1 and MCPs.39
Cognitive impairment and psychiatric features. Global cognitive
functions are largely preserved,5,6 and cognitive impairment is gene-
rally mild if present.6 Disorientation,41 inattentiveness,42,43 and psy-
chomotor retardation43 are common,13 but they are not specific for
AHD. Impairment in memory,41 frontal function,5,35 visuospatial func-
tion,6,35 and verbal fluency41 may be present, but focal cortical dysfun-
ctions such as agnosia, apraxia, or aphasia are usually absent.6,41 One
case report used the term ‘‘hepatic dementia’’ to emphasize that AHD is
associated with a treatable dementia syndrome.41 However, this term is
rarely used because the neuropsychological deficits in AHD do not
correspond with the commonly accepted definition of dementia.6
Neuropsychiatric features such as disinhibition, aggression, apathy, or
paranoia may be accompanying44 or presenting features.33,41,41,6,41AHD
may be superimposed on an acute confusional state or acute HE. Under
general circumstances, minimal HE would not be diagnosed as AHD,
but minimal HE accompanied by various movement disorders may be
given such a diagnosis based on its chronic, progressive course.
Hepatic myelopathy. Hepatic myelopathy, which is characterized by
progressive spastic paraparesis, rare sensory impairment, rare sphincter
dysfunction, and normal spinal imaging, has rarely been reported in
previous AHD studies.2,45 Excluding more common causes of spastic
paraparesis is the first step in diagnosing hepatic myelopathy,46 which
seems to occur more frequently in males than in females.1,47 In a report
describing 49 cases of hepatic myelopathy, episodes of HE were reported
in about 80% of patients,47 suggesting an association between a clinical
history of HE and hepatic myelopathy.
Differential diagnosis for Wilson disease and chronic manganism.
Similarities and differences exist among neurologic manifestations of
AHD, chronic manganism, and WD (Table 1).48 All three conditions
share clinical characteristics of various movement disorders and neu-
ropsychiatric symptoms. Limb or truncal ataxia is common in both
WD and AHD, whereas dystonia is commonly present in chronic
manganism.49 The Kayser-Fleischer (K-F) ring is a pathognomonic
sign in WD, while it is absent in AHD and chronic manganism.
Hepatic myelopathy may be present in AHD.46 A scoring system for
WD diagnosis includes K-F rings, neurological symptoms, hemolytic
anemia, 24-h urinary copper excretion, hepatic copper values,
rhodamine-positive hepatocytes, serum ceruloplasmin concentration,
and ATP7B gene mutation analysis.50 Scores >4 suggest a high
likelihood of WD, scores of 2–3 points suggest probable WD, and
scores of 0–1 points indicate that WD is unlikely. The diagnosis of
AHD and chronic manganism is based upon a relevant history (history
of liver disease or high exposure to manganese) and supportive labo-
ratory and imaging features.
Brain Imaging
Brain imaging related to parkinsonism. Symmetric high signal inten-
sity on T1WI in the globus pallidus has been consistently repor-
ted as a typical finding linked to parkinsonism in AHD patients
(Figure 3A).3,12,42,43,51–56 High signal intensity on T1WI may extend to
adjacent areas including the putamen, caudate nucleus, and midbrain,
but it is rarely seen in the cerebellum.37,57 The high signal lesions on
T1WI are thought to be the result of manganese accumulation.23,58
Similarity in the high signal intensity on T1WI, as well as overlapping
dopamine-deficient clinical syndrome in patients with AHD and those
with manganese intoxication, suggest that manganese may play an
identical role in these two conditions.59 Manganese is a paramagnetic
material that shortens the T1 relaxation time, resulting in hyperinten-
sity on T1WI without altering signal intensity on T2-weighted images
(T2WI).60 The concentration of manganese in the basal ganglia, which
corresponds to the high signal intensity on T1WI, was higher in AHD
patients than in controls.8,52,61,62 Despite contradictory results,42 high
serum manganese levels in patients with hyperintense lesions in the
basal ganglia on T1WI8 support the hypothesis that manganese plays a
key role in the development of high signal intensity on T1WI in AHD
patients.23,58 The causal relationship between MRI lesions and clinical
symptoms is not clear. Approximately 60–70% of patients with increased
signal intensities in the globus pallidus on T1WI did not develop
parkinsonism. This finding was similar to that in asymptomatic welders
in whom T1WI MRI showed a high pallidal signal.42,63 Patients who
have lesions with high signal intensity on T1WI do not necessarily
develop symptoms of AHD. The exact role of manganese in the develop-
ment of signal alterations on MRI and its effects on neurological
symptoms remain to be determined.
18F-Dopa (F-DOPA) positron emission tomography (PET) and DAT
scans have been studied in to evaluate presynaptic dopaminergic neu-
ronal degeneration in AHD patients with parkinsonism. F-DOPA has
been used as a PET radioligand to evaluate presynaptic dopaminergic
neuron integrity by measuring dopamine precursor uptake. DAT scans
shows presynaptic dopaminergic neuronal integrity by measuring the
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Table 1. Comparison between Wilson disease, AHD, and Chronic Manganism
























1) Age at onset: ,30
2) Ophthalmic: K-F rings





5) Cognition: impaired executive
function and attention deficits
6) Psychiatric: depression,
personality changes, psychosis
1) Age at onset: variable



























1) Serum ceruloplasmin: Q
2) 24-hour urinary copper: q
3) Abnormal liver function tests
4) Hemolytic anemia: present
5) Genetic testing: ATP7B mutations
1) Abnormal liver function tests
2) Normal to slightly increased
ammonia level
3) Increased manganese levels in
whole blood and CSF
may be shown
1) Increased manganese
levels in whole blood
Neuroimaging
findings
1) T2-MRI (m/c): hyperintensities
in the thalamus, lentiform and
caudate nuclei, midbrain
(‘‘face of the giant panda’’),
and cerebellum
2) T1-MRI: hyperintensities in
the globus pallidus
1) T1-MRI (m/c): hyperintensities
in the globus pallidus, putamen,
and substantia nigra
2) T2-MRI: MCP and cerebellum
3) F-DOPA and DAT scan:
conflicting results (normal
uptake and reduced uptake
of F-DOPA and DAT)
1) T1-MRI hyperintensities
in the globus pallidus
and substantia nigra
2) F-DOPA and DAT scan:
conflicting results (normal
uptake and reduced uptake
of F-DOPA and DAT)
Pathology Opalski cells, Alzheimer
type II astrocyte, cavitations
Alzheimer type II astrocyte,
polymicrocavitation, CPM/EPM
Alzheimer type II astrocyte
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Table 1. Continued
Wilson Disease AHD Chronic Manganism






























Abbreviations: BCAA, Branched-Chain Amino Acid; BRTO, Balloon-Occluded Retrograde Transvenous Obliteration; CaNa2EDTA, Calcium
Disodium Salt Ethylene Diamine Tetraacetic Acid; CPM, Central Pontine Myelinolysis; CSF, Cerebrospinal Fluid; DAT, Dopamine
Transporter; EPM, Extrapontine Myelinolysis; F-DOPA, Fluorodopa; K-F rings, Kayser-Fleischer Rings; MCP, Middle Cerebellar Peduncles;
m/c, Most Common; PAS, Para-Aminosalicylic Acid; T1-MRI, T1-Weighted Magnetic Resonance Imaging; T2-MRI, T2-Weighted Magnetic
Resonance Imaging.
Figure 3. Neuroimaging Studies in AHD with Parkinsonism. (A) Brain MRI in AHD. High signal intensities in the bilateral globus pallidus on T1-weighted
images, (B-E) (18F FP-CIT PET findings. (B) Normal controls; (C) AHD patients with parkinsonism; (D) AHD patients with parkinsonism; (E) Idiopathic Parkinson
diseases. AHD, Acquired Hepatocerebral Degeneration; 18F FP-CIT PET, 18F-N-3-Fluoropropyl-2b-Carboxymethoxy-3b-(4-iodophenyl)-Nortropane Positron
Emission Tomography; MRI, Magnetic Resonance Imaging.
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degree of uptake of radioligands that bind to DAT. DAT single-photon
emission computed tomography (SPECT) has been widely used to
diagnose presynaptic dopaminergic neuronal degeneration. DAT PET
was recently introduced to evaluate presynaptic dopaminergic neuron
integrity. Because the resolution of PET imaging is higher than that of
SPECT, DAT PET may be superior to SPECT to support diagnosing
parkinsonian syndromes, although these imaging tools have not been
directly compared.64,65 On the other hand, PET imaging using radio-
tracers including 123I-iodobenzamide,11C-raclopride, and 18F-fallypride
have been applied to evaluate postsynaptic dopaminergic receptor
density.66 Previous AHD pathology studies have demonstrated the loss
of D2 dopaminergic receptor binding, and PET studies have shown
decreased uptake of radioligands that bind to D2 receptors. Based on
such findings, dysfunction of postsynaptic dopamine receptors related to
manganese accumulation has been implicated in parkinsonism in AHD
patients.10,67,68 There is growing evidence from F-DOPA PET, DAT
SPECT, and DAT PET that supports a role for presynaptic dopa-
minergic degeneration in AHD patients. Although few studies have
described F-DOPA results in patients with AHD, they have reported
diffuse reduced uptake throughout the striatum in F-DOPA PET, in
addition to showing typical patterns of PD. Three different patterns
have been described in DAT scans of patients with AHD. The first is
normal DAT uptake, which supports the hypothesis that manganese
does not cause a loss of presynaptic dopaminergic nerve termi-
nals (Figure 3B–C).12,37,69 Secondly, AHD patients have shown scattered
or diffusely decreased putaminal radioligand uptake on DAT scans
(Figure 3D). Patients with intact dopaminergic nerve terminals or diffuse
dopaminergic deficits that differ from the typical PD pattern exhibit
symmetric parkinsonism and early gait disturbance with limited levo-
dopa responsiveness. Abnormal DAT uptake in the striatum compatible
with PD (Figure 3E) has been reported in AHD patients.13,36,69 Patients
with PD patterns on DAT scans were originally considered to have PD
superimposed on AHD, owing to clinical signs identical to those in
levodopa-responsive PD patients.36,69 However, recent evidence has led
to the hypothesis that manganese in AHD may be associated with pre-
synaptic dopaminergic degeneration.70 Studies of manganese-induced
parkinsonism may provide clues to parkinsonism pathophysiology in
patients with AHD. Manganese may aggravate alpha-synuclein dynamics
and promote its aggregation.71 Moreover, progression of manganese-
induced parkinsonism was found to depend on the dose of manganese
exposure.72 Taken together, existing findings indicate that manganese
accumulation may lead to progressive degeneration of presynaptic
dopaminergic nerve terminals. Moreover, manganese exposure may be
a risk factor for the development of PD, although the relationship
between this heavy metal and PD is still unclear.73,74 Further imaging
studies that evaluate the pathomechanism in patients with manganese
intoxication and AHD may provide clues to the diverging findings of
F-DOPA PET and DAT scans in AHD patients.
Brain imaging related to ataxia-plus syndrome. Predominant gait
ataxia with other movement disorders has been frequently reported in
AHD patients. Lesions in the cerebellum and MCP are thought to be
responsible for ataxia-plus syndrome in AHD patients.18,39,75,76 These
lesions appear as high signal intensity on T2WI (Figure 4A) with low or
isodense signal intensity on T1WI (Figure 4B). This suggests that
lesions in the cerebellum and MCP may be caused by mechanisms
other than manganese accumulation. Patients with alcoholic LC exhi-
bit distinct signal intensity changes in the corticocerebellar tract on
T2WI; these are different from the usual patterns seen in the normal
elderly population.19 Dysfunctional methionine metabolism and
dysregulation of cytokine production have been proposed as possible
pathomechanisms for white matter changes in patients with AHD.
High signal intensity on T2WI is not limited to the cerebellum and
MCP; signal changes on T2WI have also been found in the basal
ganglia and inferior corona radiata.19,43,58 Besides high signal lesions
on T2WI, isolated cerebellar degeneration has been reported in rela-
tion to ataxia-plus syndrome in an AHD patient.40
Other imaging studies. Diffuse cerebral atrophy has been observed in
patients with chronic liver disease.55,77–79 Results of voxel-based
analysis of MRI showed differences in regional gray and white matter
volumes between patients with liver cirrhosis and those with AHD.77,80
The clinical significance of cerebral atrophy or volume changes in
certain brain regions in AHD patients remains to be clarified.
Figure 4. Brain MRI findings in AHD with Ataxia-Plus Syndrome.
(A) High signal lesion on T2-weighted image and (B) low signal lesion on
T1-weighted image in the middle cerebellar peduncles Reproduced with
permission from Ishii K et al.75 AHD, Acquired Hepatocerebral
Degeneration; MRI, Magnetic Resonance Imaging.
Shin HW, Park HK Acquired Hepatocerebral Degeneration
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services8
Signal changes in the striatum can be detected earlier on proton
density-weighted (PDW) MRI than on T1WI.81 The clinical usefulness
of PDW imaging in patients with AHD remains unclear due to the
lack of studies.
MR spectroscopy (MRS), a clinically useful tool for assessing altera-
tions in brain metabolites, has been used to assess patients with HE.82,83
Typical findings include reductions in myoinositol/creatine and choline/
creatine ratios and an increased glutamine/glutamate ratio.82,83 Similar
MRS findings have been observed in patients with AHD.84
Treatment
Liver transplantation. LT is the ultimate treatment for liver cirrhosis.
Favorable outcomes of AHD following LT have been continuously
reported.2,4,8,34,35,85,86 A study comparing the outcomes of LT and
conservative management in AHD patients found that LT improved
neurological deficits and reversed MRI abnormalities, whereas
conservative medical treatment alone did not improve outcome.34
In one case series, three patients with AHD showed improvements
in cognitive dysfunction and parkinsonism.35 In contrast, many
studies have reported less favorable outcomes after LT, including
transient improvement followed by AHD recurrence,87,88 unchan-
ged neurological state,3 and newly developed AHD.3,87–89 These
poor outcomes following LT were mostly caused by failure of the
transplanted liver. The mechanism by which LT reverses neurolo-
gical deficits in AHD has not been established. Larger prospective
studies are needed to assess the effects of LT in patients with AHD.
Symptomatic management. Levodopa has been empirically adminis-
tered to manage parkinsonism symptoms in AHD.5,8,10,90 Modest to
dramatic improvement has been observed, especially in AHD patients
who had parkinsonian symptoms identical to PD. The effects of
levodopa in these patients, along with asymmetrically decreased DAT
uptake with a rostrocaudal gradient, support the presence of presyna-
ptic dopaminergic degeneration in AHD patients. Dopamine receptor
antagonists including haloperidol and quetiapine, as well as tetra-
benazine and anticholinergics, have been administered to AHD
patients to treat hyperkinetic movement disorders.38,88
Other treatments. Many anecdotal treatments have been applied to
AHD patients. In one report, trientine was administered to chelate
manganese. It was found to improve parkinsonian symptoms and
eliminate abnormal signal intensity on brain MRI.37 Branched-chain
amino acids (BCAAs) are thought to improve neurological deficits in
HE patients by competing with aromatic amino acids (AAAs) for
blood brain transport and reducing AAA entry into the brain.91,92
In a case report, BCAAs were administered to two patients with
AHD, one with parkinsonism and another with cerebellar ataxia,93
both of whom showed improvements in imaging findings and neuro-
logical deficits.93 Balloon-occluded retrograde transvenous oblitera-
tion (BRTO) is an elective treatment modality for gastric varices in
patients with LC.92 A case report described that BRTO in a patient
with AHD improved ataxia and parkinsonism and reversed abnor-
mal brain MRI signals. In addition, portosystemic shunt obliteration
via percutaneous transvenous embolization in a patient with AHD
was found to improve both cerebellar symptoms and abnormal brain
MRI findings.94
Conclusions
AHD has various clinical spectrums, each with its own distinct
pathophysiological mechanisms and neuroimaging findings. AHD can
be classified into subtypes rather than being considered a single disease
entity. LT is the most promising therapeutic strategy to ultimately
eliminate the source of the disease. Additional clinical studies and
pathophysiological and neuroimaging research including large num-
bers of patients with chronic liver disease are needed to clarify the
exact nature of AHD.
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